Study on the Clinical Efficacy and Safety of Endostar Combined with Pemetrexed and Cisplatin in the Treatment of Lung Adenocarcinoma

Objective:To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma.Methods:From August 2016 to September 2020,32 patients with lung adenocarcinoma who were treated in our hospital were selected for group trials.According to their specific treatment plan,the patients were divided into control group and experimental group,with 16 cases in each group.The control group was treated with pemetrexed and cisplatin,and the experimental group was treated with Endostar combined with the treatment received by the control group.The clinical efficacy and safety of the two regimens were assessed by comparing the changes in symptoms and the incidence of adverse reactions between the two groups of patients after treatment.Results:The disease control rate of the experimental group was significantly higher than that of the control group,and there was no significant difference in the incidence of adverse reactions between the two groups.Conclusions:From the experimental results,we found that the treatment of patients with lung adenocarcinoma by Endostar combined with pemetrexed and cisplatin can effectively improve the treatment efficacy without increasing adverse reactions and therefore relevant chemotherapy regimens can be considered for wider clinical applications.

酪酸梭菌活菌散对新生儿肺炎抗生素相关性腹泻的疗效分析

目的分析酪酸梭菌活菌散对新生儿肺炎抗生素相关性腹泻(antibiotic-associated diarrhea, AAD)的疗效。方法选取2018年1月—2019年7月某院收治的76例肺炎AAD新生儿病例,随机分为对照组和观察组,每组38例,2组均予以常规治疗,其中对照组给予蒙脱石散+去乳糖奶粉喂养,观察组给予蒙脱石散+去乳糖奶粉喂养+酪酸梭菌活菌。比较2组止泻时间、临床疗效、治疗前后肠屏障功能指标[血清细菌内毒素(serum bacterial endotoxin, BT)、二胺氧化酶(diamine oxidase, DAO)、D-乳酸(D-lactate acid, D-LC)水平]、不良反应发生情况。结果观察组止泻时间短于对照组,差异有统计学意义(t=9.033,P<0.05);2组临床疗效等级分布差异有统计学意义(Z=8.496,P<0.05),观察组总有效率高于对照组,差异有统计学意义(χ^(2)=7.710,P<0.05);治疗后2组血清BT、DAO和D-LC水平均下降(观察组:t=36.875、20.959、28.476,对照组:t=32.741、16.854、25.425,P<0.05),且观察组的各项数值均较对照组更低(t=12.082、4.745、8.310,P<0.05),差异均有统计学意义;2组不良反应总发生率差异无统计学意义(t=0.671,P>0.05)。结论酪酸梭菌活菌散治疗新生儿肺炎AAD可缩短止泻时间,提高临床疗效,改善肠屏障功能,且安全性好。